Fast Learn
-
500 shares every of PFE and JNJ generate $3,540 in annual passive earnings on a $127,000 funding at a blended 2.79% yield.
-
JNJ’s sixty fourth consecutive dividend enhance to $1.34 quarterly is backed by a AAA-rated stability sheet and $19.7 billion in free money circulate.
-
Pfizer’s 6.8% yield displays inventory compression, with CEO Albert Bourla prioritizing the dividend over buybacks whereas Padcev jumped 39% in Q1 2026.
-
Act now: the analyst who known as NVIDIA in 2010 simply named his prime 10 AI shares — and Johnson & Johnson did not make the lower. Seize the names FREE right this moment.
Passive earnings is the closest factor traders must monetary gravity. It pulls in cash whether or not you’re at your desk, on a seashore, or asleep, and it lands in your account it doesn’t matter what the broader market did that week. Earned earnings relies on exhibiting up. Dividend earnings relies on a board of administrators conserving a promise it has usually saved for many years.
Healthcare megacaps have quietly grow to be the bedrock of that promise. Two of essentially the most extensively held names within the sector, Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), write checks 4 occasions a yr to shareholders no matter what biotech sentiment, election cycles, or Treasury yields are doing. In contrast with rental property or non-public credit score, a 500-share place might be liquidated in seconds and rebalanced with out a closing lawyer.
We screened our 24/7 Wall St. dividend fairness analysis database, in search of shares that pay large dividends, and we discovered a group of firms that, mixed, can generate over $3,500 a yr in passive annual earnings should you make investments simply 500 shares in every inventory on the time of this writing.
Act now: the analyst who known as NVIDIA in 2010 simply named his prime 10 AI shares — and Johnson & Johnson did not make the lower. Seize the names FREE right this moment.
Johnson & Johnson
Johnson & Johnson is a diversified healthcare large working two reporting segments: Modern Medication and MedTech. The pharma aspect delivered $15.426 billion in Q1 2026 income, up 11.2% yr over yr, fueled by DARZALEX, TREMFYA, and CARVYKTI. The MedTech enterprise added $8.636 billion, up 7.7%, with electrophysiology and Abiomed driving cardiovascular development.
The dividend is constructed on reliability somewhat than headline yield. JNJ simply declared its sixty fourth consecutive annual dividend enhance, elevating the quarterly payout 3.1% to $1.34, payable June 9, 2026. That Dividend King standing is structural: a AAA-rated stability sheet, 21.8% revenue margins, and $19.7 billion in free money circulate final yr again each quarterly verify.
